Evaxion A/S · NASDAQ:EVAX
Evaxion A/S — SITC 2026
9 slides from Evaxion A/S's conference presentation, November 2026
Slide 1: EVX-01 personalized AI-designed vaccine plus pembrolizumab in advanced melanoma
EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma MADS LAUSEN SENIOR SCIENTIST
Slide 2: Disclosures
Disclosures • Mads Lausen is an employee of Evaxion A/S • This study was sponsored by Evaxion A/S © Evaxion A/S. All rights reserved. 2
Slide 3: Background
Background • Personalized cancer vaccines have been shown to be feasible, safe, and clinical effective in melanoma patients in an adjuvant setting • EVX-01 is a personalized peptide-based neoantigen vaccine that has shown promising early clinical activity with good safety profile • We evaluated in E
Slide 4: EVX-01: 75% Objective and 25% Complete Response Rate
EVX-01: 75% Objective and 25% Complete Response Rate BASELINE PATIENT CHARCTERSTICS All responses have been confirmed by follow-up assessments conducted in accordance with RECISTS 1.1 Male 11 (69) criteria Sex, n (%) Female 5 (31) <65 7 (44) Age, n (%) ≥65 9 (56) Ethnicity, n (%) Caucasian 16 (100)
Slide 5: EVX-01 induced T-cell immunogenicity
EVX-01 induced T-cell immunogenicity T-cell reactivity against the EVX-01 neoAg pool Immunogenicity against individual vaccine neoAgs rs=0.38 P < 0.001 89% Immunogenic vaccine neoAgs Immunogenic vaccine neoAgs, n = 105 Non-immunogenic vaccine neoAgs, n = 13 Note: All data on this slide were generate
Slide 6: Neoantigen-specific T cells are enriched for effector memory phenotypes
Neoantigen-specific T cells are enriched for effector memory phenotypes compared to non-specific T cells Ex vivo neoAg-specific T-cell CD4+ T-cell memory populations responses 1/12 NeoAg-specific CD4+ T cells Non-specific CD4+ T cells (8.3%) W78, n=9 W78, n=9 5/12 6/12 (41.6%) (50%) Total = 12 analy
Slide 7: Treatment-associated peripheral immune cell changes
Treatment-associated peripheral immune cell changes Regulatory T-cells (Tregs) Mature NK-cells W12: 12 weeks of pembrolizumab © Evaxion A/S. All rights reserved. 7 W30: Pembrolizumab + six doses of EVX-01
Slide 8: Conclusions
Conclusions • EVX-01, in combination with pembrolizumab, demonstrated: ü 75% (12/16) ORR with responses maintained through two years and up to three years with additional EVX-01 monotherapy ü Ability to induce potent & sustained T-cell responses • Evaxion’s AI-Immunology™ platform successfully (89%)
Slide 9: Acknowledgements
Poster #502 Acknowledgements Sat. Nov 7 12-1:30 p.m. 6:40-8:10 p.m. Melanoma Institute Australia, The University of Department of Health Technology, Sydney, and Mater and Royal North Shore Hospitals Technical University of Denmark (DTU) Georgina V. Long Sunil Kumar Saini QR-code Sebastian Sebbaha fo